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DERIVATION OF PURIFIED SMOOTH MUSCLE CELLS FROM 
MOUSE INDUCED PLURIPOTENT STEM (iPS) CELLS 
CHIAN YANG 
ABSTRACT 
Cardiac and vascular disease syndromes and abnormalities have long been the leading 
causes of death in the United States, but the cause of congenital defects remain unclear 
due to the lack of appropriate model systems for scientific investigation. Moreover, the 
predominance of cardiovascular disease has stimulated scientists to focus on developing 
tissue-engineered blood vessels (TEBV) for vascular reconstruction and replacement. 
Major challenges remain in generating large amounts of epithelial cells (EC) and vascular 
smooth muscle cells (VSMC) for vascular reconstruction and in reducing the 
immunoresponse in patients after replacement. To address both issues of disease model 
generation and vascular tissue engineering, we can use induced pluripotent stem (iPS) 
cells discovered by Shinya Yamanaka in 2006: iPS cells generated from adult tissue and 
organs through the forced expression of two to four transcription factors are 
phenotypically indistinguishable from embryonic stem (ES) cells. First, by creating iPS 
from cardiovascular patients, we can generate patient-specific cell lines for scientific 
research investigation (i.e. elucidate molecular mechanisms and potential drug targets). 
Second, EC and VSMC derived from patient-specific iPS cell lines can be used for 
vascular reconstruction with cells of the patient’s own genetic background, which should 
overcome many of the immunological limitations that currently impede vascular 
replacement (i.e. provide therapeutic interventions).  
  
v 
The goal of this project is to study the differentiation capacity of iPS cells into smooth 
muscle cells (SMC). This project aims to develop a protocol that can maximize the 
derivation of purified smooth muscle cells from mouse induced pluripotent stem (iPS) 
cells through three linear developmental stages: induction of a posterior primitive- streak 
(PS) like population, formation of Flk1+ mesoderm, and induction of smooth muscle 
cells. Low dosage of Activin A and Wnt was used to differentiate iPS into a PS-like 
population, while the administration of BMP4 differentiates the cells to mesoderm via a 
posterior PS intermediate.  Smooth muscle cells were induced from mesoderm by the 
addition of platelet-derived growth factor (PDGF-BB) and transforming growth factor b 
(TGF-β). The linear developmental progression from PS formation through mesoderm 
induction to smooth muscle cells were tracked by RT-qPCR and FACS for the expression 
of genes indicative of each individual stage, Flk1, and SMαA respectively. The results of 
this project can be used as a basis for in vitro derivation of purified mammalian smooth 
muscle cells from a mouse model system that can be further modified. Moreover, the 
differentiated SMCs can be further used in cell sheet construction as vascular patches for 
drug testing.     
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1. INTRODUCTION 
 
1. 1 Current treatment for cardiovascular disease 
Cardiovascular diseases and abnormalities 
have been the leading cause of death for 
several years. However, the cause of the 
congenital defects remains unclear due to the 
lack of model systems for scientific 
investigation and disease treatment. One of 
the current treatments for cardiovascular 
disease is to replace diseased vessels with 
synthetic grafts. However, since the synthetic 
grafts do not grow with age, young patients require repeated graft replacement surgeries 
during their growth period. Current research has focused on engineering cell sheets to 
construct vessels in vitro and then implanting the vessels to repair the damaged vessels 
(Hibino et al., 2011). Cell sheets can be made by patterning endothelium cells (EC) and 
vascular smooth muscle cells (VSMC) in vitro to imitate the construction of blood 
vessels in vivo (Fig1.1). The organization of blood vessels in vivo usually is in three 
layers or tunics: the intima, media, and adventitia. The tunica intima is a thin layer of 
endothelial cells (EC) that line the lumen or interior of the vessels. The tunica media 
contains vascular smooth muscle cells (VSMC), which actively change the diameter of 
the vessels. The tunica adventitia is the outermost layer, composed mostly of fibrous 
Fig 1.1 The construction of blood vessels 
(Cited from 
http://crescentok.com/staff/jaskew/isr/). 
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connective tissue. Its function is basically to support and protect the vessels. Therefore, to 
construct the vessels in vitro, there are two main considerations. One is how to generate 
large amount of EC and VSMC in vitro. The second is how to prevent immunogenicity.  
 
1. 2 Stem cell research in cardiovascular regeneration 
Although mature VSMC can be cultured in vitro, their limited proliferation potential and 
easily senescence have prevented them from being applied as the source for cell sheet 
construction (Bajpai, et al., 2012). Embryonic stem cells (ESC) are a powerful source for 
cardiovascular regeneration because they have the unique potential to differentiate into 
almost any cell type including all the cardiac and vascular lineages. However, the biggest 
hurdle for ESC application in either scientific investigation or clinical therapies lies in the 
ethical and political controversies. The derivation of ESC from one embryo requires the 
depredation of the blastocysts. However, the creation of induced pluripotent stem (iPS) 
cells by Shinya Yamanaka in 2006 has presented a new opportunity for stem cell research 
and application in disease treatments (K Takahashi et al., 2006). The major property that 
defines iPS cells is their functional capacity to differentiate into almost any cell type 
similar to the functional pluripotency of ESC. Moreover, although iPS cells are 
experimentally derived cells that are generated in vitro from somatic tissues, their 
epigenetic states and gene expression level are visually indistinguishable from ESC 
(Yamanaka, 2012). The major advantage of iPS over other pluripotent stem cells is in 
their source of origin: iPS cells can be derived from almost any somatic tissue, and this 
advantage has lead to the development of patient-specific cell lines (CQ Xie, et al., 2009) 
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which can be used for disease investigation and treatment (TH Lee, et al., 2009) Taking 
cardiovascular disease for instance, iPS cells can be derived from a patient’s hair or any 
somatic tissue and then be differentiated into SMC, EC or cardiomyocytes and be 
reintroduced into the patient’s body after the genetic defects are repaired. In this way, 
because the cell source is from patient himself, it is unlikely to provoke the immune 
response (Araki, et al., 2013). On the other hand, when the iPS cells are produced from 
patients with unknown etiology, the iPS cells can be used for scientific investigation in 
vitro to determine the cause of the disease (Fig 1.2).  
 
 
 
 
Fig 1.2. Schematic illustration of the generation of iPS cells and how these 
cells can theoretically be employed to study 1) molecular mechanisms in 
vitro or 2) used for therapeutic interventions in humans (Boheler, 2010). 
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1. 3 The application of mouse model systems in disease investigation 
 
Current scientific research has been using mouse model systems for disease investigation 
(Yoshida, A., et al., 2012). There are several reasons to rely on mouse models in disease 
modeling. First, both mouse and human are mammalian; over 99% of mouse genes have 
a direct counterpart or homogeneous genes in humans. Second, the successful integration 
of foreign DNA into the mouse genome in 1980 has allowed scientists to investigate 
experimentally the roles of genes in development, physiology and disease. For instance, 
the insertion of foreign DNA usually results in a gain of function or in the over-
expression of endogenous genes (ex: knock-in). The deletion of one specific endogenous 
gene results in a loss-of-function (ex: knock-out) or in a decrease in expression of 
endogenous genes (ex: knock-down). Therefore, transgenic mice have become a realistic 
human pathology model for modification involving the introduction of a foreign DNA 
sequence/fragment into a mouse egg. Third, the mouse embryonic development is very 
similar to human embryonic development; therefore, by using mouse model system, we 
can gain a better conceptual understanding of embryogenesis (M. Baker, 2008). 
 
One of the most important events during embryogenesis is the generation of three 
primary germ layers: ectoderm, endoderm, and mesoderm during the process of 
gastrulation (Fig 1.3A) (Murry and Keller, 2008). Each germ layer has distinct 
differentiation potentials. For instance, the ectoderm has the ability to differentiate into 
neural cells and skin while the mesoderm has the ability to differentiate into heart, blood, 
vascular smooth muscle and skeletal muscle. The endoderm can differentiate into liver, 
lung, pancreas and other organs. In the mouse system, gastrulation starts from the 
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formation of the primitive streak (PS) (Fig 1.3B). The PS can be divided into three 
regions: posterior region, middle region and anterior region. These three regions differ in 
their gene expression patterns and developmental potential. For example, the epiblast 
cells that migrate toward the posterior side will exit as mesoderm while the epiblast cells 
that migrate toward the anterior side will give rise to the definitive endoderm. Unlike the 
formation of the mesoderm and endoderm, the formation of ectoderm derives from the 
epiblast cells in the anterior region that do not migrate across the PS. Previous research 
has indicated that different regions of the PS are responsible for the induction of specific 
lineages because they are composed of different signaling environments (Nostro, et al. 
2008). For example, Nostro et al. has shown that Activin A/Nodal and Wnt are two 
signaling factors required for PS formation while BMP4, though not responsible for PS 
formation, has a dominant effect over Activin A and Wnt in programming the formation 
of the posterior streak population. Strong Activin A/Nodal signaling will induce epiblast 
cell migration toward the anterior region to form the definitive endoderm, while the 
administration of BMP4 will inhibit the formation of endoderm and induce the epiblast 
cells to migrate toward the posterior PS region to become mesoderm. Nostro et al. also 
elucidated that all three signaling factors are required for the induction of mesoderm.  
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1. 4 Previous research on in vitro VSMC differentiation  
 
The VSMC developmental lineages start from the formation of posterior PS to the 
induction of mesoderm and then to the generation of VSMC (Fig 1.4). Previous research 
has shown that several signaling factors, including platelet-derived growth factor (PDGF-
BB) and transforming growth factor b (TGF-β), may contribute to the development of 
Fig 1.3. Mouse Gastrulation and Germ Layer Formation  (A) The derivatives of the 
three primary germ layers: ectoderm, mesoderm and endoderm generated during 
gastrulation.  (B) Gastrulation in the mouse embryo. Shown are the posterior and 
anterior regions of the posterior streak (Murry CE, Keller G , 2008.) (Cell Volume 
132, Issue 4 2008 661 – 680). 
 
  
7 
VSMC from embryonic stem cells (Qingzhong Xiao, 2010); however, the precise 
molecular mechanism remains unclear. One study has indicated that exogenous TGF-β 
induces mouse embryonic 10T1/2 cells to express α-SMA, and that antibody-mediated 
inhibition of TGF-β reduces expression of α-SMA and SM-MHC (smooth muscle myosin 
heavy chain) (Hirschi et al., 1998). Another study has shown that the administration of 
PDGF-BB results in selective induction of α-SMA cells with spindle-like shapes 
resembling VSMC. Therefore, this study concluded that PDGF-BB signaling is required 
for vascular integrity through involvement in pericyte proliferation and recruitment to the 
vascular wall. (Yamashita et al., 2000).  
 
While studies investigating the response of cells to exogenous growth factors yield some 
insight, they do not definitively reveal whether or not endogenous signaling factors are 
required for SMC development. Loss-of-function studies must be carried out in order to 
support the finding that TGF-β and/or PDGF-BB are specific factors regulating SMC 
differentiation. Moreover, α-SMA is not a specific marker for smooth muscle cells 
because many other cell types also express α-SMA (Sinha et al., 2004). In addition, the 
spindle-like shape is not specific for SMC but is displayed in other cell types as well. 
Moreover, although previous studies provide evidence that TGF-β-treated cells express 
more α-SMA and SMMHC than untreated cells, the studies relied on use of the antibody 
that shows low sensitivity for murine SMMHC, which likely has high cross-reactivity 
with nonmuscle myosin heavy chains. In summary, whether TGF-β and/or PDGF-BB are 
the signaling factors that regulate SMC differentiation remains unclear and requires more 
study to reveal their role in regulating SMC development. This project aims to examine 
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whether TGF-β and PDGF-BB are both required for the SMC differentiation in iPS 
cells. Through the administration of different dosage combinations of TGF-β and PDGF-
BB, the iPS cells were tested for gene expression of α-SMA by qPCR and FACS. The 
morphological changes of the cells were observed optically and the contractility assay 
was utilized to examine cell contraction.  
  
Fig 1.4. ESC Differentiation 
in Culture. This model 
depicts the regulation of 
primitive streak formation, 
primary germ layer 
induction, and tissue 
specification from 
differentiated mouse ESCs. 
The first step in the 
differentiation pathway is 
the development of a 
population resembling the 
epiblast of the mouse 
embryo. When induced 
with Wnt, activin, BMP4, 
or serum, these cells will 
generate a primitive streak 
(PS)-like population. 
Following PS induction, the 
posterior PS cells (yellow) 
are specified to Flk-1+ 
mesoderm. The pathways 
that specify Flk-1 
mesoderm to the vascular 
smooth muscle lineage are 
marked as red circle 
(Murry CE, Keller G , 
2008.) (Cell Volume 132, 
Issue 4 2008 661 – 680). 
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2. SPECIFIC AIMS 
 
The aim of this project is to develop a methodology to optimize the derivation of smooth 
muscle cells (SMC) from mouse induced pluripotent stem (iPS) cells reprogrammed from 
mouse tail-tip fibroblasts (TTFs). Fig 2.1 is the schematic diagram of the SMC 
differentiation process. A six-month-old α-SMA-hrGFP transgenic mouse will be used 
for the generation of TTFs. The transgenic mouse had been inserted with a plasmid, 
which has a smooth muscle alpha actin (α-SMA) promoter that directs the expression of 
humanized Renilla Green Fluorescent Protein (hrGFP) genes (Ghosh S. et al., 2011). All 
the mouse cells (including SMC and TTFs) that contain α-SMA are able to turn on the 
GFP gene and display green fluorescence. Therefore, our hypothesis is that once TTFs 
are reprogrammed into iPS cells, the somatic signaling will be switched off. Since iPS 
cells no longer contain α-SMA, the GFP gene will then be turned off. GFP gene will be 
turned on back again when we induce SMC differentiation from iPS. The reason to use 
the α-SMA-GFP transgenic mouse in this study is because we believe that the on/off 
stages of GFP gene can be viewed as an indication of the open/close stages of the 
somatic signaling pathways that represent the transformation between somatic cells 
and pluripotent cells.  
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The TTFs were generated from mouse-tail fragments and then injected with the published 
stem cell cassette (STEMCCA) (Sommer et al. (2009 & 2010)). STEMCCA is a lentiviral 
vector that incorporates a pluripotency cassette which contains four reprogramming 
transgenes, Oct-3/4, Klf4, Sox2 and cMyc. The cassette is flanked by two loxP sites that 
will allow the pluripotency cassette to be excised in the presence of Cre recombinase 
after the formation of iPS (Fig 2.2). The TTFs were integrated with STEMCCA for 24 
hours and then left in the mouse embryonic stem (MES) medium for one week to ten 
days to reprogram into iPS. The reprogrammed iPS, were picked up and cultured in the 
plates containing the inactivated mouse embryonic fibroblasts (MEF) as the feeder layer 
with MES medium. The MEF feeder layer and the leukemia inhibitory factor (LIF) in the 
MES medium support the growth of iPS and keep the iPS cells in the undifferentiated 
stage. The differentiation process starts from the formation of embryoid bodies (EB) by 
putting iPS in suspension culture with completely serum-free differentiation media 
(cSFDM) for 72 hours. The iPS then started to differentiate when suspension-cultured in 
Fig 2.1. The schematic diagram of SMC differentiation process.  
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media without LIF and serum. After 72 hours, the EBs were switched to the cSFDM 
containing a low dosage of Activin A, Wnt, and BMP4 for another 48 hours. According 
to Nostro et al., after the addition of the three signaling factors, the EBs first differentiate 
into the PS and then into mesoderm. When the quantity of mesoderm reaches a 
maximum, the combination of different dosages of PDGF-BB and TGF-β were applied 
for the induction of SMC.  
Fig 2.2. Schematic representation of the STEMCCA–loxP lentiviral vector. A 
loxP site was introduced within the U3 region of the 30 LTR. Upon formation 
of the provirus, a floxed version of each STEMCCA vector is produced. 
Following exposure to Cre, the entire cassette is excised (Sommer et al., 2010). 
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Specific Aim 1: Develop methodologies for the derivation of smooth muscle progenitors 
from reprogrammed somatic cells 
 
Mouse tail-tip fibroblasts (TTFs) were reprogrammed into mouse iPS cells using the 
published stem cell cassette (STEMCCA), a lentiviral vector that transfers 4 
reprogramming transgenes (Oct4, Klf4, Sox2, and cMyc) into somatic cells in order to 
derive pluripotent cells. Mouse iPS cells were then differentiated into smooth muscle 
progenitors through lineage developmental stages from posterior primitive-streak 
formation to mesoderm induction by exogenous administration of three growth factors: 
human Activin A, mouse Wnt3a and human BMP4. The STEMCCA integration copy 
number was determined by PCR. The pluripotency characteristic of the reprogrammed 
mouse iPS was tested by immunofluorescent staining of pluripotency marker proteins 
including SSEA-1, and Oct4. The developmental stages of smooth muscle differentiation 
were monitored by RT-qPCR for quantitative detection of RNA expression of 
mesodermal markers, Flk1, and SMC markers, SMA, SM22, and SMMHC. FACS was 
also used to quantify the percentage of cells exhibiting mesodermal Flk1 expression and 
SMAGFP expression.  
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Specific Aim 2: To test the role of PDGF-BB and TGFB in the differentiation and 
maturation of iPS cell-derived smooth muscle 
 
The role of PDGF-BB and TGFB in smooth muscle cell induction was determined by 
treating the smooth muscle progenitors with a combination of different dosages of PDGF-
BB and TGF-β. The differentiation process was monitored by RT-qPCR for quantitative 
detection of RNA expression of smooth muscle alpha actin (α-SMA) and other SMC 
differentiation markers. The fluorescent GFP expression, which is driven by α-SMA 
promoter inside the transgenic mouse model, was also observed by the fluorescence 
microscopy, and SMAGFP expressing cells were quantified and purified by flow 
cytometry for a) RNA extraction for RT-qPCR studied detailed above, and b) replating in 
cultures (supplemented with PDGF-BB and TGF-b) to test the proliferative and 
expansion potential of the purified SMA-GFP positive population.  
 
Specific Aim 3: To test the effect of residual reprogramming transgene expression on the 
capacity of iPS cells to undergo directed differentiation to smooth muscle lineages 
 
After the TTFs were successfully reprogrammed into iPS cells, the STEMCCA was 
removed from the cells through cre-excision. The cre-excision was monitored by PCR. 
The differentiation capacity of the same iPS clone with STEMCCA-integration and with 
STEMCCA-deletion was compared.  
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3. MATERIALS AND METHODS   
 
3.1 Mouse model system 
A smooth muscle alpha actin-green fluorescent protein (α-SMA-hrGFP) transgenic 
mouse that expresses humanized Renilla reniformis GFP (hrGFP; stratagene, Cedar 
Creek, TX) under the control of the 5kb rat α-smooth muscle actin (SMA) gene promoter 
was used in this study. This transgenic mouse (Shamik Ghosh, at al, 2011) was a gift 
from Dr. Alan Fine’s lab in the pulmonary center at Boston University School of 
Medicine. 
 
3.2 Lung inflation and fixation 
The mouse lungs were fixed with 4% paraformaldehyde (PFA) in PBS pH 7.4 overnight 
at 4°C. The fixed lungs were washed with PBS 30 min on ice and rinsed in 7.5% sucrose 
in PBS pH 7.4 for six times. The fixed lungs were put in 30% sucrose in PBS pH 7.4 
overnight at 4°C and then washed with fresh 30% sucrose one hour on rotor at 4°C before 
freezing. Sucrose was used as cryoprotectant, which is used to protect biological tissue 
from freezing damage caused by ice formation. The fixed lungs were cut into small 
pieces and put separately into cryomolds filled with optimum cutting temperature 
(O.C.T), the embedding medium. The fixed lungs were frozen in nitrogen-cooled 
isopentane for about 30 seconds and stored at -80°C.  
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3.3 Immunohistochemistry staining of the fixed lung section 
The frozen lungs were sectioned and put at room temperature in the dark one to two 
hours for drying. The sections were washed with PBS twice, each time for 5 min. 
Blocking buffer with 10% donkey serum in PBS was applied to the section one hour at 
room temperature in the dark. The biotinylated anti-α-SMA antibody was used as the 
primary antibody staining and applied for an hour at room temperature. The sections were 
washed twice with PBS, each time for 10 min.  Streptavidin conjugated with Cy3 dye 
was used as the secondary antibody and applied to the section for 30 min. The sections 
were then washed twice with PBS and covered with Prolongold (Invitrogen, Carlsbad, 
CA). 
 
3.4 Cell culture and growth conditions 
Mouse Embryonic Fibroblasts (MEF) medium for fibroblasts culture 
Primary tail-tip fibroblasts (TTFs) and mouse embryonic fibroblasts (MEFs) were grown 
in complete mouse embryonic fibroblast (MEF) medium that contains Dulbecco's 
modified eagle's medium (DMEM, Gibco) with 15% fetal bovine serum (FBS), 2mM L-
glutamine (Gibco), and 1% Penicillin/Streptomycin (Gibco). 
 
Mouse Embryonic Stem cell (MES) medium for iPS cell culture 
iPS cells were grown on a plate with MEFs underneath. MEFs were put on a plate with 
MEF medium one day before plating the iPS cells. Before plating iPS, the MEF medium 
was changed to complete mouse embryonic stem cell (MES) medium which contains 283 
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ml DMEM with 50 ml ESC (embryonic stem cell) qualified FBS, 3.5ml L-glutamine 
(2mM final conc.), 3.5ml Penicillin/Streptomycin (1% final conc.), 350,000 units of 
Leukaemia inhibitory factor (380 µL LIF) and 2.38ul of 2-mercaptoethanol (0.1 mM final 
concentration). 
 
complete Serum Free Differentiation medium (cSFDM)  for EB formation 
After derived from MEFs, iPS cells were cultured in cSFDM, which contains 100 ml 
serum free differentiation (SFD) medium, 26 µl MTG (Sigma M6145), 1 ml L-glutamine 
(200 mM, Invitrogen, 25030-081) and 1 ml Ascorbic Acid, but no serum and LIF. 
Because there was no serum and LIF, iPS cells were then automatically differentiated 
into EBs. SFD contains 375 ml IMDM, 125 ml F12cellgro (Cellgro, 10-080-CV), 5 ml 
B27+RA (Invitrogen, 17504-044), 2.5 ml N2 supplement and 3.3 ml 7.5% BSA in PBS 
(Invitrogen, 15260-037). 
 
cSFDM with Activin/Wnt 3a/BMP4 for the induction of PS and mesoderm 
After 48-hour (from D0 to D2) cultured in cSFDM, EBs were switched to cSFDM 
medium with the addition of low dosage of Activin (2ng/ml), Wnt (3ng/ml), and BMP4 
(0.3 ng/ml) for another 48 hours (from D2 to D4). 
 
cSFDM with 10% serum for the induction of SMC as a control  
On Day 4, the cells were switched to cSFDM medium with 10% serum and were 
observed under the fluorescent microscope daily until some cells expressed GFP.   
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cSFDM with different dosage combinations of PDGF-BB/TGF-β for the induction of 
SMC 
On Day 4, the cells were switched to the cSFDM medium with different dosage 
combinations of PDGF-BB and TGF-β for the induction of smooth muscle cells. 
 
3.5 Preparation of fibroblasts from α-SMA-hrGFP transgenic mouse tail-tips 
Tail-tip fibroblasts (TTFs) were derived from the mouse tail fragments from the α-SMA 
transgenic mouse. Tails snipped from the transgenic mouse were sterilized with 
phosphate-buffered saline (PBS) with penicillin and streptomycin. The outside skin was 
removed from the tail by peeling back the superficial dermis. The tail was then cut into 1-
cm pieces and each fragment was put into one well of a gelatin-coated12-well plate. The 
tail fragments were then cultured according to standard methods to expand TTFs in 2 ml 
of MEF medium for 5 to 7 days. After fibroblasts migrated out of the tail fragments, the 
fragments were then removed from the plate and the adherent fibroblasts were re-fed with 
fresh media every two days. The cells were ready to be passaged after reaching 90% 
confluence. TTFs were infected with STEMCCA lentivirus at passage 3 to reprogram 
into iPS cells. 
 
3.6 Mouse iPS cell generation with STEMCCA 
100,000 fibroblasts were plated the day before infection in four wells of a gelatin-coated 
6 well plate. The old MEF medium in each well was replaced with 1 ml fresh MEF 
medium with the additional of 5 µg/ml of polybrene. 2, 5, and 10 µl of STEMCCA 
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lentivirus was added into the first three wells respectively, and the last well was left 
without virus as a control. The plate was incubated at 37°C for 24 hours. The media was 
removed from the wells after overnight culture and replaced with 2 ml of fresh MES 
medium to stop the infection. The MEF medium was changed every two days until small 
colonies appeared. Once the colonies were large enough and rounded in shape, the well 
was washed with PBS and then covered with 1 ml PBS. Colonies were marked under the 
microscope and picked up by a 20 µl pipette with a clean tip. The tip was used to cut 
away a colony from its surrounding MEFs, and then the colony was aspirated into the 
pipette with 20 µl PBS. The picked colony was then transferred into a well of a 96-well 
plate with round-bottom and added with 40 µl trypsin-EDTA. The colony was pipetted up 
and down several times in trypsin-EDTA medium in order to get single cells and then 
transferred into another 96-well plate previously plated with MEFs and160 µl MES 
medium. This process was repeated for every selected colony. Once again, when small 
colonies appeared in each well, the medium was changed every two days until the 
colonies became large enough to be passaged. The colonies were washed with PBS and 
then trypsinized for 2 minutes, after which the trypsinization was stopped by the addition 
of ES medium. The cell suspension was then transferred into one well in a 12-well plate 
previously coated with MEFs. The colonies were then transferred into a 6-well plate after 
reaching 90% confluence.  
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3.7 Cre-excision of the STEMCCA cassette from mouse iPS cells  
Desalting AdenoCre virus:  
A column (llustra ProbeQuant G-50 microcolumns) was briefly vortexed before spinning 
down for 1 min at 2000 RPM. The column was washed with 400 µl of sterile 10 % 
glycerol in PBS and spun down for 30 sec at 2000 RPM. The washing step was repeated 
three times, and the last spin was 1 min. The column was transferred from the washing 
tube to a sterile eppendorf tube. 15 µL adenovirus with 50 µL of 10% glycerol in PBS 
was added into the column directly into the resin. The column was spun down for 2 min 
at 2000 RPM and kept on ice until use. 
 
MEFs were coated on a new 6-well plate one day before performing Cre-excision. 
Confluent iPS colonies in one well of the original 6-well plate were trypsinized to a 
single cell suspension and were transferred into another well without MEFs for 30 mins 
for MEF depletion.  Within 30 min, MEFs re-attach to the plate while iPS cells float in 
the medium. The iPS supernatant was collected and counted. 75,000 cells were 
transferred into an eppendorf, spun down, and resuspended again in 250 µl of MES 
media. 3 µl of the adenovirus was added into the eppendorf tube and was placed at 37⁰C 
in a 5% CO2 incubator for 4 hours while flicking the tube every 30 min. 30 µl, 70 µl, and 
150 µl of cells and virus were placed in 3 wells of the MEF-coated 6-well plate, 
respectively, with 1.5 mL of MES medium. After 24 hours infection, the medium was 
aspirated and changed with fresh medium. This process was repeated for every selected 
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colony. Once again, when small colonies appeared in each well, the medium was changed 
every two days until the colonies became large enough to be picked into 96-well plate.  
 
3.8 gDNA isolation for PCR analysis 
The removal of the pluripotency cassette, STEMCCA, was confirmed by PCR analysis 
after extracting DNA from each clone. For DNA isolation, each clone was first cultured 
in one well of the 6-well plate. When each well reached 80% confluence, the old MES 
medium was aspirated and the plate was washed twice with PBS. The cells were 
trypsinized for 1 min and MES medium was added to stop trypsinization. The cells were 
transferred into a 15-ml conical tube for 5-min centrifugation at 300 rcf in 4°C. The 
supernatant was aspirated to yield a cell pellet. The cell pellet was resuspended in 30 µl 
PBS and transferred into a 1.5 mL eppendorf tube. 512.5 µl of master mix (12.5 µl 
proteinase K per 500 µl tail buffer) was added into each sample tube for contaminating 
protein digestion. Each sample was mixed well and put in a 50°C water bath for 
overnight incubation. The next day, each sample was well vortexed in order to break up 
clumps. 512.5 µl of isopropanol was added to each sample for DNA precipitation. Each 
sample was centrifuged at 9300g for 2 min, and the supernatant was aspirated. 500 µl of 
70% ethanol was added into each sample and mixed well. The sample was centrifuged 
again and the supernatant was aspirated off. The samples were then quickly re-spun for 
another 30 sec to remove the remaining ethanol. The samples were allowed to dry for one 
hour, and 50 µl TE buffer was added for resuspension. The samples were stored at 4°C 
overnight. More TE buffer was added for DNA resuspension.  
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3.9 PCR analysis 
The following procedure was used for pluripotency cassette removal confirmation PCR. 2 
µl of extracted DNA sample was added to 12.5µl of PCR GoTaq (Thermo scientific) plus 
1.25 µl forward and 1.25 µl reverse primers (Table 3.1) with 8 µl water. The PCR 
conditions used were as follows: 
• 95°C for 3 min  
• 94°C for 30 sec  
• 60°C for 30 sec  
• 72°C for 90 sec  
• Go to step2 x29  
• 72°C for 5 min  
The PCR product was analyzed on a 2% agarose gel that was run at 120V for 1.5 hours. 
The gel was imaged using a SynGene Gene Genius Bio Imaging System. 
Table 3.1 Primers used for PCR analysis 
Primer 
name Sequence 
E2A 5' 5'- CGC TTT GTT GAA ACT CGC -3' 
WPRE 3' 5'- AAG CAG CGT ATC CAC ATA GC -3' 
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3.10 Immunofluorescence staining 
Cells were grown in a MEF-coated 12-well plate until 80% confluent and then fixed with 
4% paraformaldehyde/PBS for 15 min at room temperature and then washed twice with 
PBS. The cells were then permeabilized using 1% Triton X-100/PBS for 10 min at room 
temperature and then washed twice with PBS. A blocking solution containing 4% normal 
goat serum/PBS was applied to the cells for 30 min at room temperature. The cells were 
then incubated with diluted primary antibodies (Table 3.2) for 1 hour at room temperature 
and then washed three times with PBS. The cells were then incubated with diluted 
secondary antibodies for another 30 min at room temperature in the dark. Subsequently, 
10 µl of diluted DAPI staining was added into each well for nucleus staining. The cells 
were observed under the fluorescent microscope. When the cell nuclei received sufficient 
DAPI staining, the cells were then washed three times with PBS with 1 ml PBS left in 
each well to prevent cells from drying out.  
Table 3.2 Primary and secondary antibodies used for immunofluorescence 
Primary 
Antibody Ig 
Stock 
Concentration 
(µg/ml) 
Dilution Supplier 
Oct3/4 Mouse IgG 200 1:100 Santa Cruz 
SSEA1 IgM 100 1:50 Millipore 
SSEA4 IgG 100 1:50 Millipore 
Secondary 
Antibody Fluorochrome 
Stock 
Concentration 
(µg/ml) 
Dilution Supplier 
Goat anti 
mouse IgG 546-Alexa 200 1:200 Invitrogen 
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3.11 Embryoid Body (EB) formation 
One well from a 6-well plate with 80% confluent cells was trypsinized for 1-2 min. 2 ml 
MES medium was used to stop the trypsinization. The cell suspension was put in a 15 ml 
conical tube and spun down for 5 min. The supernatant was aspirated to leave only the 
cell pellet. The cell pellet was resuspended with 10 ml MES medium and put into a P100 
tissue culture dish for 30-40 min in the 37°C incubator for MEF depletion. During this 
period, most MEFs re-attached on the dish while the iPS cells remained suspended in the 
medium. After 30-40 min, the supernatant was collected and spun down for another 5 
min. The cell pellet was resuspended with 1 ml cSFDM and counted. 1 million cells were 
plated in a P100 petri dish with 10 ml cSFDM for 48 hours in order to make EBs.  
 
3.12 Posterior primitive streak (posterior PS) and mesoderm induction  
After 72-hour EB formation, the cell suspension was collected in a 15 ml conical tube 
and was allowed to settle for 15 min. During this period, EBs precipitated to the bottom. 
Some dead cells or debris remained in the supernatant layer. Therefore, aspirating the 
supernatant removed the debris and dead cells but kept most EBs intact. The EBs were 
gently resuspended in 10 ml cSFDM with a low dosage of Activin/Wnt/BMP4. The cell 
suspension was plated in a P100 petri dish for another 48 hours for posterior PS and 
mesoderm formation. 
 
3.13 Smooth muscle cell induction 
On Day4, the EB suspension was collected in a 15 ml conical tube and was spun down 
  
24 
for 1 min. The supernatant was aspirated, and the cell pellet was resuspended with either 
cSFDM with 10% serum or cSFDM with low dosage combinations of PDGF-BB/TGF-β. 
The cell suspension was plated in a 12-well tissue culture plate for reattachment and 
differentiation. Cells were observed under the fluorescent microscope for GFP expression.   
 
3.14 FACS 
FACS was used to isolate Flk1 and GFP positive cells after 72 hours culturing in cSFDM 
with growth factors. Day 0 cells were used as Flk1 and SMAGFP negative controls. For 
each sample, isotype staining and primary antibody staining were prepared. The isotype 
staining was used to confirm the specificity of primary antibody binding to rule out non-
specific fluorescent receptor binding to cells or other cellular protein interactions. 
Medium was aspirated from cells to be tested via FACS, and then the cells were washed 
with PBS. The cells were trypsinized with 1 ml cold trypsin in a 37°C water bath for 
exactly 1 min and neutralized with 1 ml ES FBS. The cells were centrifuged at 1100 rpm 
for 5 min. The cell pellet was resuspended in 1 ml PBS plus 2% ES FBS. One half 
million cells were collected into each eppendorf tube and resuspended in 100 µl of PBS 
plus 2% ES FBS for isotype staining and primary antibody staining. After 30 min 
staining, the cells were washed with PBS plus 2% ES FBS and spun down at 600 g for 5 
min. The cells were resuspended in 400 µl of PBS plus 2% ES FBS and put into a sterile 
FACS tube. The tube was then inserted into the BD FACSan machine. The Flk1 and GFP 
positive cells were isolated and collected into a sterile FACS tube containing 1ml cell 
specific medium. 
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Flow cytometry was used to assess the peak of mesoderm and to check the expression of 
KDR and GFP in iPS colonies. Medium was aspirated from cells to be analyzed, and the 
cells were washed with PBS. The cells were then trypsinized and centrifuged at 1100 rpm 
for 5 min. The cell pellet was resuspended in 400µl of PBS plus 2% ES FBS and counted. 
One half million cells were collected for both isotype staining and primary antibody 
staining. After a half-hour staining, the cells were washed with PBS plus 2% ES FBS and 
spun down at 600 g for 5 min. The cells were resuspended in 400 µl of PBS plus 2% ES 
FBS and pipetted into a sterile FACS tube. The tube was then inserted into the BD 
FACsan flow cytometer, where the GFP expression was calculated for the smooth muscle 
cell population, and the KDR expression was calculated for mesoderm induction. 
 
3.15 Real-time PCR analysis 
The sorted cells from each sample were put in RLT buffer with β-ME and stored at -80⁰C 
for RNA extraction. RNA was isolated with an RNeasy mini kit (Qiagen). cDNA was 
transcribed using Promega reserve transcription system. Quantitative real-time PCR 
(qPCR) was performed in a StepOne Plus instrument (Applied Biosystems, Foster City, 
CA). Reactions were normalized to 18S rRNA. All TaqMan probes were purchased from 
Applied Biosystems.  After PCR, a melting curve was constructed in the range of 60-
95⁰C to evaluate the specificity of the amplification. See Table 3.3 for the details of 
TaqMan probes.  
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 Table 3.3 TaqMan probes used for qPCR analysis 
Gene Company Primer ID 
Kdr (Flk1) Applied Biosystems Mm01222421_m1 
Acta2 Applied Biosystems Mm00725412_s1 
SM22 (Tagln) Applied Biosystems Mm00441661_g1 
SMMHC (Myh11) Applied Biosystems Mm00443013_m1 
Collagen1a1 (Col1a1) Applied Biosystems Mm00801666_g1 
Rbp1 Applied Biosystems Mm00441119_m1 
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4. RESULTS 
 
4.1 Immunohistochemistry of the fixed lung tissue 
 
The immunohistochemistry staining (IHC) of the fixed lung section was used to confirm 
whether the α-SMA-hrGFP transgenic mouse had been successfully inserted with the α-
SMA-hrGFP plasmid. Fig 4.1 shows that GFP fluorescence is bright in cells that have the 
morphology of smooth muscle cells, confirming the reporter works well in vivo in 
vascular smooth muscle cells in the lung. However, the immunostaining could not be 
reliably interpreted due to autofluorescent red artifacts on the section, particularly in the 
airway epithelium and alveolar macrophages.  
SMAGFP 
SMA-Cy3 
Fig 4.1. The immunohistochemistry staining of the fixed lung section from SMA-
hrGFP transgenic mouse. The primary antibody is anti-smooth muscle actin 
conjugated with biotin while the secondary antibody is streptavidin conjugated 
with cy3 dye. The green expression is from the SMAGFP plasmid.  
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4.2 Primary culture of TTFs 
 
TTFs were generated from a α-SMA-GFP transgenic mouse as described in previous 
research section. Fig 4.2 shows the growth of TTFs from mouse tail fragments after 
cultured in a 12-well plate from D5 to D13. The tail was first cut into pieces and put 
separately into a 12-well plate. After five-day culture at 37°C, some small cells migrated 
out from the fragments. After an additional ten days, the cells proliferated and their 
morphology changed from sphere-like to spindle-like. Fig 4.3 shows the GFP expressed 
fibroblasts. The tail-tip fibroblasts, when cultured on the plate, they behaved like 
myofibroblasts. Therefore, TTFs were able to turn on the GFP genes located on the α-
SMA-GFP promoter and expressed green.  
Fig 4.2 The growth of TTFs from five to ten more days. 
D5 D6 D7 
D8 D9 D10 
D11 D12 D13 
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4.3 Reprogramming TTFs into iPS 
 
iPS cells were generated from mouse TTFs as described in section 3.5. Fig 4.4 shows the 
morphological changes of TTFs during the reprogramming process. After infection with 
5 µl of STEMCCA for 24 hr, the cells were switched from a MEF medium to MES 
medium. The morphology of some cells began to change from spindle-like to sphere-like 
and became small clones. When observed under the microscope, the small clone-like 
cells did not express green, which indicates that the cells were unable to turn on the GFP 
Fig 4.3 The GFP-expressed TTFs 
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gene. This is consistent with our hypothesis that when the TTFs reprogrammed into 
iPS cells, the somatic signaling pathways inside those cells were switched off, and the 
cells were being transferred into the pluripotent stage. As there was no α-SMA 
inside the iPS cells that can drive the expression of SMAGFP, the GFP gene was 
then turned off, and the iPS cells could not display green fluorescence.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.4 The formation of small iPS clones during the reprogramming process. ‘A’ is a 
small clone observed in day 5. ‘B’ is another small clone observed in day 7. ‘C’ is a third 
clone observed in day 10(1 is the phase contrast image. 2 is the fluorescent image. 3 is the 
overlay of 1 and 2.). 
  
A1 
A2 
A3 
B1 
B2 
B3 
C1 
C2 
C3 
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4.4 Confirmation of pluripotency  
The small clone-like cells were then picked up and passaged from a 96-well plate into a 
12-well plate. When the cells in the 12-well plate reached 80% confluence, the cells were 
passaged into another 6-well plate. Fig 4.5 shows the morphology of mature iPS after 1 
passage.  
 
 
 
 
 
  
Fig 4.5 The morphology of iPS 
  
32 
The pluripotency of the iPS cells was confirmed by alkaline phosphatase staining and 
immunofluorescence staining.  
 
Fig 4.6 is the alkaline phosphatase result. It shows that cells were positively stained (red).  
Fig 4.7 is the immunofluorescence staining of Oct3/4, SSEA1 and DAPI. It shows that 
the cells not only successfully expressed Oct3/4 transcription factor in the nucleus, but 
also expressed the SSEA1 on the surface of the membrane. However, the positive 
staining of Oct3/4 may come from two places; the integrated STEMCCA cassette which 
contains Oct4 as one of the reprogramming factors or from the cells’ endogenous Oct3/4, 
which indicates the cells were successfully reprogrammed into iPS. Since Oct3/4 staining 
was not enough for the confirmation of pluripotency, SSEA1 was used to double-check 
the pluripotent stage of the cells. SSEA1 was chosen because it is not in the cassette, and 
DAPI DAPI Oct3/4 SSEA1 
Fig 4.6 The alkaline phosphatase staining of iPS 
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it is strongly expressed in MES cells. Fig 4.7 shows that the cells strongly expressed both 
Oct3/4 and SSEA1, which illustrates that the cells successfully express the pluripotent 
markers.  
 
 
 
 
 
 
 
 
  
 Fig 4.7 Oct3/4 and SSEA1 immunofluorescence staining of iPS  
DAPI DAPI 
Oct3/4 SSEA1 
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4.5 Cre-excision of STEMCCA 
After the pluripotency of iPS cells was confirmed, the STEMCCA needed to be removed 
from the iPS cells in order to generate virus-free iPSc. Expression of the STEMCCA 
transcript was analyzed by polymerase chain reaction (PCR). Fig 4.8 shows the PCR 
results of four clones with STEMCCA integration. The band appearing in each lane 
represents the gene fragment of STEMCCA cassette.  
 
 
The cre-excision of STEMCCA was confirmed by PCR analysis as well. Fig 4.9 shows 
the cre-excision of the selected four clones. Four samples were chosen from each clone: 
One was the sample before cre-excision (STEMCCA-integrated clone) and another three 
were the cre-excised progenies from each clone. It is obvious that all the STEMCCA-
integrated samples had the representative band of STEMCCA cassette and all the cre-
excised, except one, had no band of STEMCCA cassette. It indicates that the cre excision 
success was > 90%.  
 
 
 
 
 
Fig 4.8 Confirmation of STEMCCA integration of four clones. 
(PCR:E2A 5’/WPRE 3’) 
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4.6 Differentiation process 
 
4.6.1 72 hours EB formation 
Cells were differentiated as described in the previous section. When cells were put in 
cSFDM medium with no LIF and serum, the cells began to differentiate. The formation 
of embryoid body, or EB, is a three-dimensional aggregation of ES, which occurs in the 
case of in vitro culturing the iPS or ES cells. Previous research has indicated that in vitro 
EB formation mimics in vivo embryogenesis, which goes through gastrulation and 
comprises the three embryonic germ layers: ectoderm, mesoderm, and endoderm (Monya 
Baker, Nature 2008). Fig 4.10 shows the morphology of EB formation before (Fig 4.10A) 
and after (Fig 4.10B) the addition of Activin, Wnt, and BMP4. At the beginning of the 
differentiation process, the cell lines proliferated slowly and took 72 hours (3 days) to 
form small EBs (Fig 4.10A) characterized by morphology that was not so round. 
However, the addition of Activin on Day3 altered the morphology of the small EBs to 
become round and well-defined (Fig 4.10B). This could be because Activin can activate 
cell proliferation.  
 1 2 3 4 
Fig 4.9 Confirmation of STEMCCA deletion of the four selected 
clones. The lanes with number on top are the pre-cre samples 
while the following lanes without number on top are their cre-
excised colonies. It is obvious that STEMCCA cassette in one of 
the cre-excised colonies from the second clone (#2 clone) was not 
successfully removed.  
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4.6.2 The induction of posterior primitive streak and mesoderm 
4.6.2.1 The percentage of Flk1+ cells on D5 is higher in cre-excised clone 
To test the effect of residual reprogramming transgene expression on the capacity of iPS 
cells to undergo a directed differentiation process to smooth muscle lineages, the 
STEMCCA-integrated clone and one of its cre-excised progenies were selected to go 
through the same differentiation process, and their capabilities to generate Flk1+ cells 
were compared on Day5. Fig 4.11 shows the comparison of the FACS results between 
two samples (STEMCCA-integrated and Cre-excised). The result shows that on Day5, 
after 48 hours cultured in cSFDM with Activin (2ng/ml), Wnt (3ng/ml), and BMP4 
(0.3ng/ml), 85.9% cells in the cre-excised sample became Flk1 positive, while only 
31.4% cells in the STEMCCA-integrated sample became Flk1 positive. The isotype 
control for each sample was used to confirm the specificity of the primary antibody (anti-
Fig 4.10 The morphology of EBs formation before the addition of Activin, Wnt, and 
BMP4 (A. 72 hours in cSFDM) and after the addition of Activin, Wnt, and BMP4 (B. 48 
hours after the addition of Activin, Wnt, and BMP4). The morphology of EBs became 
much rounder after the addition of growth factors. 
A
.
B
.
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Flk1) to rule out non-specific fluorescent receptor binding to the cells. The experiment 
was repeated three times, and the statistical data is shown in Fig 4.12.  
 
 
 
 
Fig 4.11. The comparison of the FACs results between two clones: STEMCCA-integrated 
clone and its Cre-excised progeny. The top two plots were generated from STEMCCA-
integrated clone: Isotype control and stained sample while the bottom two plots were 
generated from the Cre-excised progeny. 
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Fig 4.12 shows that the p-value is 0.0054 which is below 0.05. This indicates that there is 
a significant difference between the percentage of Flk1+ cells of the two clones. In other 
words, although the percentage of Flk1 positive cells varies from trial to trial, the results 
are always the same; the percentage of Flk1+ cells on day5 is always higher in cre-
excised clone. This result is consistent with a previously published paper, which has 
shown that excision of reprogramming transgenes improves the differentiation potential 
of iPS cells (Sommer et al., 2010).  
 
4.6.2.2 SMAGFP+ cells derive from Flk1+ precursors 
To determine whether SMAGFP+ cells derive from Flk1+ precursor or Flk1- cells, Flk1+ 
cells were sorted from Flk1- cells on Day 5 and plated separately in 10% serum for 7 
days to induce the formation of SMC. On Day 12, the two groups of cells were FACS-
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Fig 4.12 The bar graph of the average percentage of Flk1+ cells generated from three 
trials. The average percentage for cre-excised clone is 73.5% while the average 
percentage for STEMCCA-integrated clone is 14.3%. SD value for each sample is 10.58 
for cre-excised clone and 15.45 for STEMCCA-integrated clone. P value is 0.0054. 
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sorted to determine differences between the percentages of SMAGFP+ cells derived from 
each group. Fig4.13 is the schematic diagram of the experiment.     
 
Fig 4.14 is the FACS result from Day 12. The result shows that after 7 days culture in 
10% serum condition, only 3% of the flk1- cells became SMAGFP+ while 32% of the 
flk1+ cells became SMAGFP+. This means that SMAGFP+ cells derived 
predominantly from Flk1+ precursors. Moreover, most SMAGFP+ cells generated 
from Flk1+ cells no longer have Flk1 expression, which suggests that Flk1+ cells appear 
to have lost Flk1 expression during the differentiation process.  
Fig 4.13. The schematic diagram of the process to determine whether 
SMAGFP+ cells derive from Flk1+ precursors or Flk1- precursors. 
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4.6.3 Induction of Smooth Muscle Cells Using TGF-β and PDGF-BB 
4.6.3.1 Different dosage combinations of PDGF-BB and TGF-β have similar percentage 
of SMAGFP+ expression 
Different dosage combinations of PDGF-BB and TGF-beta were added on Day 5 to 
induce the formation of smooth muscle cells. On Day 12, the cells were analyzed with 
FACS to quantify differences between SMAGFP+ cells derived from each sample. Fig 
4.15 shows that there is no significant difference between SMAGFP+ cells derived from 
Fig 4.14  FACS results from Day 12. The two plots on the first column were the D0 
samples and were used as a standard control: Isotype and AntiFlk1. The two plots on 
the second column were generated from Flk1- group while the next two plots were 
generated from Flk1+ group.  The last two plots were from the presorting D5 samples. 
The result shows that there were 32% of the Flk1+ cells become SMAGFP+ under 
cultured in 10%serum for 7 days and SMAGFP+ Cells derived predominantly from 
Flk1+ precursors. Flk1+ cells appear to have lost Flk1 expression in the GFP+ 
population. 
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different combinations. The percentage of SMAGFP+ cells derived from each sample is 
between 10-16%. Therefore, we are unable to determine the optimal combination 
between the two factors from the result.  
 
Fig 4.16 compares the efficiency of the two methods (10% serum vs. PDGF-BB/TGF-β) 
for the generation of SMAGFP+ cells. It shows that 30.5% of cells became SMAGFP+ 
after cultured in 10% serum for 7 days while only 10-16% (in this particular plot 15.8%) 
of cells became SMAGFP+ after cultured in the cocktail medium composed of PDGF-BB 
and TGF-β. This indicates that 10% serum is a much more efficient method than cocktail 
medium for the induction of SMAGFP+ cells. However, whether the derived SMAGFP+ 
Fig 4.15 FACS results of Day 12 cells after cultured in different dosage combination of 
PDGF-BB and TGF-β for 7 days in order to induce the formation of smooth muscle cells. 
Different dosage combinations of PDGF-BB and TGF-β have similar percentage of 
SMAGFP+ expression. 
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cells are smooth muscle cells or still myofibroblasts still needs to be determined. qPCR 
can be used to determine whether the derived SMAGFP+ cells are SMC or 
myofibroblasts.     
 
4.6.3.2 Determination of the Flk1 and SMC gene expressions in each sample 
Cells were separated into two groups on Day 5: one group was plated in 10% serum for 7 
days while another one was plated in the cocktail combination for 7 days. Then, on Day 
12, SMAGFP+ cells were sorted from the SMAGFP- cells in each group. The RNA from 
each sample (SMAGFP+/- from 10% serum; SMAGFP+/- from cocktail solution) was 
extracted and the cDNA was constructed for running the qPCR. The qPCR result was 
analyzed to determine whether there is any difference between the smooth muscle gene 
expression levels between each sample. The schematic diagram of this experiment is 
shown in Fig 4.17.  
Fig 4.16. The comparison between the efficiency of the two methods: 10% serum vs. 
PDGF-BB/TGF-β. It shows that there are 30.5 % of cells became SMAGFP+ after 
cultured in 10% serum for 7 days while there are only 10-16% (in this case 15.8%) of 
cells became SMAGFP+  after cultured in PDGF-BB/TGF-β for 7 days.  
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Fig 4.17  Schematic diagram of the process to determine the different smooth 
muscle gene expression levels in each sample.  
Fig 4.18. The qPCR analysis of six different gene expressions. A is Flk1 expression. B is SMA 
expression. C is  SM22 expression. D is SMMHC expression. E is Col1a1 expression. F is 
Rbp1 expression. The qPCR analysis indicates the differentiation protocol successfully 
induces the derivation of Cells that are expressing smooth muscle markers. The abbreviation 
for each sample is D0 = Day 0, D5 = Day 5, PT_G- = PDGF-BB/TGF-β GFP negative, 
PT_G+ = PDGF-BB/TGF-β GFP positive, S_G- = 10%serum GFP negative, S_G+ = 
10%serum GFP positive. 
 
A 
B 
C 
D 
E 
F 
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Fig 4.18 shows the qPCR result of six different probes. The first one (Fig 4.18A) is Flk1, 
which is a specific marker for mesoderm differentiation. The qPCR analysis shows that 
there is a significant fold induction on Day 5 sample, which illustrates that cells were 
successfully induced into mesoderm on Day 5. In addition, it is also obvious from Fig 
4.18A that the fold induction on all Day 12 samples (PT_G+, PT_G-, S_G+, S_G-) is 
much lower than the Day 5 sample. This indicates that along the differentiation process, 
as the cells differentiate into the downstream lineages such as smooth muscle cells, the 
cells lose the expression of Flk1 and start to express other lineage markers. This is 
consistent with previous FACS results shown in Fig 4.14 that SMAGFP+ cells seem to 
lose Flk1 expression. Therefore, the qPCR analysis of Flk1 illustrates that cells were 
successfully differentiated into mesoderm on Day 5 by using this protocol, and they 
were induced into downstream lineages as they lost the Flk1 expression on Day 12.   
 
SMA, or smooth muscle alpha actin is an early stage marker during the smooth muscle 
differentiation process. The qPCR analysis (Fig 4.18B) shows that there is a significant 
fold induction of SMA with both serum and cocktail conditions when they are both GFP 
positive. This is consistent with our hypothesis that GFP positive samples should have 
higher SMA expression because the GFP gene is located on the SMAGFP plasmid. 
Therefore, only cells with smooth muscle alpha actin can turn on the GFP gene and 
display green. There is a small increase in the GFP negative samples, which may simply 
be the baseline expression of these mesodermal cells. However, what is interesting is that 
with serum, there is a much higher induction of the gene expression. 
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SM22 is a later marker after SMA during the smooth muscle differentiation process. The 
qPCR analysis (Fig 4.18C) shows a similar pattern as the SMA result. With GFP positive 
cells, there is more induction of the gene expression as compared to the GFP negative 
cells. Again, serum-treated cells appear to have higher induced gene expression than 
cocktail-treated cells. SMMHC, or smooth muscle myosin heavy chain, is an even later 
marker during smooth muscle differentiation process. The qPCR analysis (Fig 4.18D) 
shows a similar pattern although with a much smaller induction. This makes sense 
because SMMHC is a later smooth muscle marker. Taken all three qPCR analyses 
together, this shows that GFP+ cells have induction of multiple smooth muscle 
markers, which indicates that our protocol successfully differentiates iPS cells into 
smooth muscle cells.    
 
In terms of qPCR results with the last two markers; Col1a1 (Fig 4.18E) and Rbp1 (Fig 
4.18F), it's hard to understand what they represent for. Collagen 1a1 is a marker for 
myofibroblast, while the Rbp1 is a marker for synthetic smooth muscle cells. Therefore, 
since both the GFP positive cells from the serum condition and cocktail condition have 
induction of multiple smooth muscle markers, Col1a1 and Rbp1 were then expected to be 
lower in both conditions. However, the qPCR result of Col1a1 (Fig 4.18E) shows that 
serum induces the genes more than the cocktail condition and that the GFP+ cells have a 
much higher induction. The qPCR analysis of the Rbp1 marker (Fig 4.18F) further shows 
that the GFP positive cells from the cocktail condition have higher expression levels of 
Rbp1. The two qPCR results are contradictory to our expectations and it is difficult to 
make any conclusions as to whether the GFP positive samples still contain some 
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myofibroblasts or synthetic smooth muscle cells. Thus, more markers need to be tested 
and more trials need to be performed.  
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5. CONCLUSIONS AND FUTURE WORK DIRECTIONS 
 
The data in section 4.6.2.1 confirms that the removal of the STEMCCA from the iPS 
cells increase the differentiation capacity of iPS cells as was previously observed by 
Sommer et al., (2010). The FACS result shows that 85.9% of cre-excised cells became 
Flk1+ after cultured in cSFDM with Activin, Wnt, and BMP4 for 48 hours while only 
31.4% of STEMCCA-integrated cells became Flk1+ after 48 hours. However, more 
samples from longer time points will be needed to determine whether the efficiency of 
STEMCCA-integrated cells differentiation into Flk1+ cells will increase or decrease in a 
temporal pattern compared to cre-excised cells.  
The rationale of the design this protocol to first differentiate iPS cells into mesoderm and 
then differentiate the mesoderm into smooth muscle cells was to recapitulate the 
sequence of developmental milestones involved in smooth muscle formation in vivo, i.e. 
to form mesodermal Flk1+ precursors prior to their differentiation into SMA+ putative 
smooth muscle cells. The hypothesis was that SMAGFP+ cells should derive from Flk1+ 
precursors, just like the smooth muscle cells are derived from mesoderm in vivo. The 
FACS data in Fig 4.14 supports this hypothesis: more than 30% of Flk1+ cells became 
SMAGFP+ after culture in 10% serum for 7 days whereas only 3% of the Flk1- cells 
became SMAGFP+. Therefore, SMAGFP+ cells predominantly derive from Flk1 
precursors. However, future directions should focus on determining how to increase 
the percentage of SMAGFP+ cells derived from Flk1+ cells. Also, the identity of the 
remaining 54.1% cells (in the lower left zone, Q4 region of the Flk1+ plot in Fig 4.14) 
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that are not SMAGFP+ that have lost Flk1 expression should be determined. It is 
important to know whether those SMAGFP-/Flk1- cells are induced into other 
downstream lineages.   
 
We were unable to determine the optimal dosage combination of PDGF-BB and TGF-β 
in induction of smooth muscle cells from the FACS data shown in section 4.6.3.1. More 
replicates are needed to determine whether the percentage difference of SMAGFP+ cells 
in each sample is significant or not. Also, cells cultured in cSFDM without the addition 
of any signaling factors for additional 7 days after Day 5 should be used as a negative 
control to investigate whether there are any significant differences between the 
percentages of SMAGFP+ cells derived from the negative control and from the cocktail 
medium.  
 
The qPCR analysis in Fig 4.18 shows that it is possible to use this experimental 
methodology to induce the derivation of cells that are strongly expressing smooth 
muscle markers such as SMA (Fig 4.18B), SM22 (Fig 4.18C) and SMMHC (Fig 
4.18D). However, as there is still high expression of Col1a1 (Fig 4.18E) and Rbp1 (Fig 
4.18F) in the GFP+ samples, the cell type (smooth muscle cells vs. myofibroblasts) and 
the phenotype (contractile vs. synthetic) of those GFP+ cells still needs to be determined 
by testing the samples with more smooth muscle specific markers and myofibroblast 
specific markers. In addition, immunostaining with different antibodies should be applied 
as well. In addition, the fold-induction of primary smooth muscle cells and myofibroblast 
cells should be used in the future as the positive and negative controls in order to 
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determine whether the fold-expression levels of the experimental samples are significant. 
Therefore, further experiments should focus on extensive comparison of these GFP+ 
cells to primary smooth muscle cells and primary myofibroblast cells. Moreover, 
more replicates are needed to determine reproducibility of the protocol, and more 
phenotyping should focus on determining whether contractile, synthetic, 
myofibroblastic, or other SMA+ lineages are being derived, as well as their state of 
maturation.  
 
Future directions should also focus on generating iPS cells from other somatic tissues to 
investigate if there is any difference in the percentage of SMAGFP+ cells derived from 
the iPS cells generated from different somatic tissues. The differentiation capacity of iPS 
generated from different somatic tissues should then be compared. After the percentage 
of SMAGFP+ cells derived from iPS cells via this differentiation protocol is maximized 
and well-controlled, how to apply the purified SMAGFP+ cell population in cell sheet 
construction and in engineered vascular constructs should then be determined.  
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